Full Press Release Details
Verify to continue
To continue, please confirm that you're a human (and not a spambot).
Checking if the site connection is secure
vimeo.com needs to review the security of your connection before
proceeding.
KURA Neutral Sentiment
Dr. Erba offers insight into the KOMET-007 Phase 1 trial and rationale for investigating ziftomenib in combination with standards of care for the treatment of patients with newly diagnosed or R/R NPM1-m or KMT2A-r AML
Key Takeaway: The article discusses Dr. Erba's insights regarding the KOMET-007 Phase 1 trial. It focuses on the investigation of ziftomenib in combination with standard treatments for newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) with specific genetic mutations. However, the content does not provide detailed findings or outcomes from the trial.
Price reaction · baseline $13 (2023-12-19T16:46:00.000Z) · hit during market hours · 2 other KURA headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic